EWTX (Edgewise Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EWTX Edgewise Therapeutics Inc EWTX
28 GF Score
Price $42.15
! 3 Warning Signs
View Full Analysis

What is Edgewise Therapeutics 5-Year Yield-on-Cost %?

Edgewise Therapeutics EWTX +0.51% 28 5-Year Yield-on-Cost % is 0.00 as of Sep. 04, 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 149 Biotechnology companies, Edgewise Therapeutics ranks worse than 671140.27% on this metric.

Edgewise Therapeutics's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Edgewise Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



EWTX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Edgewise Therapeutics  (NAS:EWTX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Edgewise Therapeutics 5-Year Yield-on-Cost % Related Terms

EWTX vs DYN, PBLS, CELC: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Edgewise Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edgewise Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's 5-Year Yield-on-Cost % falls into.


EWTX
28GF Score
Edgewise Therapeutics Inc EWTX
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edgewise Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Edgewise Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Edgewise Therapeutics (EWTX) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Edgewise Therapeutics and its competitors. According to the industry distribution chart, Edgewise Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry.
Is Edgewise Therapeutics' 5-Year Yield-on-Cost % too high?
Edgewise Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Edgewise Therapeutics ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' 5-Year Yield-on-Cost % compare to DYN and PBLS?
According to the Biotechnology industry distribution chart, Edgewise Therapeutics ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places Edgewise Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Edgewise Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edgewise Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edgewise Therapeutics Business Description

Address 1715 38th Street, Boulder, CO, USA, 80301
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score

Get the complete analysis for EWTX

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.15
Price